Global Gene Therapy Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of Deals Signed Since 2016 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Gene Therapy Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.

Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene therapy deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter gene therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals. This report contains a comprehensive listing of 688 gene therapy deals announced since 2016 including financial terms where available including links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The report also includes numerous table and figures that illustrate the trends and activities in gene therapy deal making since 2016.

A comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter Highlights

The initial chapters of this report provide an orientation of gene therapy dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading gene therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene therapy dealmaking with a brief summary followed by a comprehensive listing of gene therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of gene therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene therapy technology type in focus.

Gene Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gene therapy collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financial terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene therapy dealmaking

2.1. Introduction

2.2. Gene therapy deals over the years

2.3. Most active gene therapy dealmakers

2.4. Gene therapy deals by deal type

2.5. Gene therapy deals by therapy area

2.6. Gene therapy deals by industry sector

2.7. Deal terms for gene therapy deals

2.7.1 Gene therapy deals headline values

2.7.2 Gene therapy deal upfront payments

2.7.3 Gene therapy deal milestone payments

2.7.4 Gene therapy royalty rates

Chapter 3 - Leading gene therapy deals

3.1. Introduction

3.2. Top gene therapy deals by value

Chapter 4 - Most active gene therapy dealmakers

4.1. Introduction

4.2. Most active gene therapy dealmakers

4.3. Most active gene therapy deals company profiles

Chapter 5 - Gene therapy contracts dealmaking directory

5.1. Introduction

5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

Deal directory

Deal directory - Gene therapy deals by company A-Z

Deal directory - Gene therapy deals by deal type

Deal directory - Gene therapy deals by therapy area

For more information about this report visit https://www.researchandmarkets.com/r/f9cy4k

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.